Author

D. Medina

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Ecology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:behavioral assay· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Amoresano· 1 shared A. Bartke· 1 shared A. Carissimo· 1 shared D. Rodriguez· 1 shared E. R. Hascup· 1 shared F. Pane· 1 shared G. Becker· 1 shared J. Hite· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Amoresano

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Coinfection with chytrid genotypes drives divergent infection dynamics reflecting broad epidemiological patterns

T. Carvalho, D. Medina, L. P. Ribeiro, D. Rodriguez, T. S. Jenkinson, G. Becker, L. F. Toledo, J. Hite

The paper investigates how coinfection with different chytrid genotypes affects virulence and transmission, finding that coinfection can increase virulence in less competitive genotypes and favor more virulent panzootic genotypes.

bioRxiv · Sep 28, 2022Ecology

Sexual Dimorphic Metabolic and Cognitive Responses of C57BL/6 Mice to Fisetin or Dasatinib and Quercetin Cocktail Oral Treatment

Y. Fang, D. Medina, R. Stockwell, S. McFadden, K. Quinn, M. R. Peck, A. Bartke, K. N. Hascup, E. R. Hascup

This study examines sex-specific effects of senolytic treatments in mice, finding that Fisetin benefits males but not females, while D+Q harms females and has little effect on males.

bioRxiv · Nov 8, 2021Physiology

Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin

M. Mariniello, R. Petruzzelli, L. Wanderlingh, R. La Montagna, A. Carissimo, F. Pane, A. Amoresano, D. Medina, R. Polishchuk

The paper identifies FDA-approved drugs that overcome ATP7B-mediated cisplatin resistance in ovarian cancer cells through synthetic lethality screening.

bioRxiv · Jul 3, 2019Cancer Biology